MUNICH, June 16, 2026 /PRNewswire/ — Innovative Molecules GmbH ("IM"), a clinical-stage biopharmaceutical company focused on herpesvirus-mediated diseases, today announced the advancement of its virology pipeline with the addition of a novel Epstein-Barr Virus (EBV) antiviral program. The program,…

Read the full release →

News provided by PR Newswire.